Fierce Pharma
JUNE 11, 2024
Right after signing on to help with bird flu pandemic preparedness efforts in the U.S., CSL Seqirus has agreed to do the same in Europe through a vaccine supply pact. | The vaccine maker will deliver 665,000 doses of its avian flu-matched pre-pandemic vaccine. Under a 4-year contract, authorities can purchase up to 40 million doses.
MedCity News
JUNE 11, 2024
Iqirvo failed as a treatment for the fatty liver disease MASH, but the drug is now FDA approved in primary biliary cholangitis. An Intercept Pharmaceuticals drug already treats this rare liver disease and Gilead Sciences is poised to compete with its PBC drug approaching an FDA decision this summer. The post Ipsen, Genfit Drug That Missed in MASH Wins FDA Approval in a Much Rarer Liver Disease appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 11, 2024
Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes. | Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami.
MedCity News
JUNE 11, 2024
A report conducted by ATI Advisory and commissioned by Better Medicare Alliance found that Medicare Advantage beneficiaries have lower healthcare spending than fee-for-service Medicare enrollees. This is true across racial and ethnic groups, according to the report. The post Report: MA Beneficiaries Spend $2,500 Less on Healthcare Than Traditional Medicare Beneficiaries appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
JUNE 11, 2024
As Gilead Sciences awaits the progression of California state litigation over its alleged delay of safer HIV drugs, the company is biding its time with a proposed $40 million settlement t | More than 2,000 plaintiffs accused the HIV drugmaker of purposely waiting to launch safer TAF-based meds in the early 2000s in order to maximize profits from its older TDF-based products.
MedCity News
JUNE 11, 2024
Getting would-be investors—and the right kind of investors—to notice and care about your company requires a robust strategy. The post Navigating the Tricky Climate of Health Tech Funding appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JUNE 11, 2024
An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busting drug support its approval. The independent advisors on the Peripheral and Central Nervous System Drugs Advisory Committee voted by 11 to zero that donanemab’s benefits outweigh its risks, and by the same margin that the data submitted by Lilly to support its efficacy was convincing.
Fierce Pharma
JUNE 11, 2024
Once hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorde | Once hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorder.
Pharmaceutical Technology
JUNE 11, 2024
AstraZeneca's sNDA for Tagrisso has obtained FDA priority review for unresectable, Stage III EGFRm non-small cell lung cancer.
Fierce Pharma
JUNE 11, 2024
As the U.K. braces for a potential government shake-up ahead of its general election next month, the country’s premier biopharma trade organization is throwing down the gauntlet. | The Association of the British Pharmaceutical Industry is challenging U.K. political parties to blueprint their plans to unlock the nation’s healthcare industry potential, according to a press release issued Monday.
MedCity News
JUNE 11, 2024
America should be a global leader in healthcare. Instead, we rank last among our peers, and outmoded regulations are holding us back. The post How Regulatory Ambiguity is Impeding Healthcare Innovation appeared first on MedCity News.
pharmaphorum
JUNE 11, 2024
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).
MedCity News
JUNE 11, 2024
As with so many other conditions, in vascular health, patients often need to be seen within a few days or weeks, but current referral systems drag on for many weeks and months. The post How Good Referral Pathways Impact Vascular and Overall Health appeared first on MedCity News.
pharmaphorum
JUNE 11, 2024
The Association of the British Pharmaceutical Industry (ABPI) is calling on political parties contesting the general election to spell out their plans to nurture and drive growth in the life sciences sector and deliver for patients.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
MedCity News
JUNE 11, 2024
South Florida-based Mount Sinai Medical Center announced a new remote patient monitoring and chronic care management partnership with HealthSnap, a Miami-based virtual care management platform. The partnership is aimed at improving outcomes among the health system’s Medicare population. The post Mount Sinai Medical Center Taps HealthSnap to Improve Chronic Conditions Management appeared first on MedCity News.
pharmaphorum
JUNE 11, 2024
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael R Carazo Salas, founder and CEO of CellVoyant, an AI-first biotechnology company spun out from the University of Bristol.
Clear Pivot
JUNE 11, 2024
One of the best ways to find aging deals in your sales pipeline is to build a report that specifically highlights them. Here's how we do that in HubSpot.
pharmaphorum
JUNE 11, 2024
CSL Seqirus will provide 665,000 doses of bird flu vaccine to the European Commission to protect at-risk workers and guard against a potential outbreak
PharmaTimes
JUNE 11, 2024
Alzheimer’s and Parkinson’s disease are responsible for more than 30 million cases globally
pharmaphorum
JUNE 11, 2024
GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead. Just over a week ago, Judge Vivian Medinilla of Delaware Superior Court issued an order ruling that cases claiming Zantac (ranitidine) could cause cancer were “admissible”, sparking a sell-off in GSK shares that wiped billions off its market cap.
Pharmaceutical Technology
JUNE 11, 2024
Discover how Amphastar Pharmaceuticals' patented medication delivery system prevents premature discharge during storage. Secure, moisture-controlled storage for medication devices.
pharmaphorum
JUNE 11, 2024
Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTimes
JUNE 11, 2024
The leading cause of cancer globally accounts for an estimated 1.
Scott’s Directories
JUNE 11, 2024
Navigating the diverse healthcare landscape of Alberta requires a strategic approach, particularly for pharmaceutical companies aiming to connect with medical professionals in both urban centers and rural areas. With a comprehensive list of doctors in Alberta at your disposal, you can tailor your outreach to meet the unique needs of various regions.
Copyright Clearance Center
JUNE 11, 2024
CCC joined forces with other industry stakeholders to launch the Leiden Institute for FAIR and Equitable Science (LIFES). In recognition of the challenges that exist with data reuse within the global research community, LIFES is a joint effort by an international public-private partnership of eleven academic and private organizations to build a wide and diverse network of public and private members that want to incorporate FAIR data principles (Findable, Accessible, Interoperable, Reusable) and
Scott’s Directories
JUNE 11, 2024
Navigating the healthcare landscape to connect with doctors can be challenging, especially for busy sales reps. In Nova Scotia, leveraging efficient strategies can make all the difference. Here, we discuss five top doctor lead generation strategies that will streamline your outreach and help you connect with healthcare professionals effectively. 1. Harness the Power of the Nova Scotia Doctors Directory One of the most effective tools at your disposal is the Nova Scotia Doctors Directory.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PM360
JUNE 11, 2024
Calcium+Company, a leading mid-sized diversified health communications group, is pleased to announce the promotion of Bruno Brasileiro from Executive Creative Director to Chief Creative Officer, based in the New York office. Brasileiro is an award-winning creative leader with more than 20 years of experience working in a variety of therapeutic categories and for a wide range of leading consumer and pharmaceutical clients.
Quantified
JUNE 11, 2024
The pharmaceutical industry is changing fast, driven by AI. This technology is transforming how training teams work. Our recent webinar, “From Hype to Results: Practical Strategies for AI Enablement of the Field Force,” featured insights from Shawn Moran of ZS and Hallie Lynch from Quantified. Here’s a summary of the key points and a call to action to watch the full recording.
Pharmaceutical Technology
JUNE 11, 2024
Discover Purdue Pharma's innovative tamper-resistant opioid analgesic dosage form with extended release properties. Learn about the patented solid oral form designed for controlled drug release and enhanced safety in medication administration.
PharmExec
JUNE 11, 2024
A Q&A with Egon Zehnder’s Sergio Della Zassa about what biopharma executives and search firms are looking for in terms of table stakes skill sets and “unicorn” experiences from top talent in the field.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
332 
Let's personalize your content